“After careful consideration, the Board has concluded that a change in executive leadership is needed as Gubra continues to implement its 2030 strategy,” says Monika Lessl, Chair of the Board. “The Board is confident that Kristian and Zoë bring the right combination of competencies and experience to build on Gubra’s progress and execute its strategy, while preserving the company’s unique culture and values.On behalf of the Board, I would like to thank Markus for his leadership and contributions to Gubra. We wish him all the best for the future.”

Gubra’s 2030 strategy, presented on October 27, remains unchanged. Under the strategy, the Danish company aims to scale up its innovation engine and expand its portfolio of clinical-stage assets across proprietary, partnered, and venture programs. Disciplined capital allocation will guide investment across its Biotech, CRO, and Ventures businesses.

Kristian Borbos

Kristian Borbos joined Gubra as Chief Financial Officer (CFO) in 2022. He brings more than 25 years of experience in finance and capital markets, including his previous role as CFO of Ascelia Pharma. Earlier in his career, Kristian held finance and investor relations positions at Novozymes, Ørsted (formerly DONG Energy), and Danske Bank. He holds an M.Sc. in Finance from Lund University, Sweden.

Zoë Johnson

Zoë Johnson joined Gubra in 2026 as Head of Gubra Ventures & Business Development. She brings more than 25 years of international experience in pharmaceutical R&D, biotechnology, and venture creation. Previously, she served as Chief Scientific and Development Officer at Molecule to Medicine and held Chief Scientific Officer positions at Affivant (a Roivant company) and iOnctura, as well as senior R&D roles at UCB, Merck Serono, and NovImmune.
Zoë holds a Ph.D. in Pharmacology from King’s College London, UK.